Verona Pharma plc
VRNA
Peringkat dalam Saham
#2232
Verona Pharma plc is a biopharmaceutical company currently in its clinical... Verona Pharma plc is a biopharmaceutical company currently in its clinical development phase, focusing on the research, development, and eventual market launch of new therapies for respiratory illnesses where current treatments are inadequate. Its primary experimental medication is ensifentrine, an inhaled compound designed to simultaneously block both phosphodiesterase (PDE) 3 and PDE4 enzymes. This unique mechanism allows it to function both as a bronchodilator, helping to open the airways, and as an anti-inflammatory agent within a single drug. Ensifentrine is presently undergoing advanced (Phase 3) clinical trials to evaluate its effectiveness in treating chronic obstructive pulmonary disease (COPD), asthma, and cystic fibrosis. To provide versatile administration options, the company is developing ensifentrine in three distinct formulations: a nebulizer solution, a dry powder inhaler (DPI), and a pressurized metered-dose inhaler (pMDI). Verona Pharma plc was established in 2005 and conducts its operations from its headquarters in London, United Kingdom.
Harga Saham
$106.91
Terakhir disinkronkan: 2025-10-07
Kapitalisasi Pasar
$9.09B
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
0.00%
Negara
GB
Perdagangan Verona Pharma plc (VRNA)
Kategori
Healthcare
Rasio P/E untuk Verona Pharma plc (VRNA)
Rasio P/E per October 2026 TTM: -63.64
Menurut laporan keuangan dan harga saham terbaru dari Verona Pharma plc, rasio P/E saat ini (TTM) adalah -63.64. Pada akhir 2023, perusahaan memiliki rasio P/E sebesar -27.61.
Riwayat rasio P/E untuk Verona Pharma plc dari 2005 hingga 2026
Rasio P/E di akhir setiap tahun
| Tahun | Rasio P/E | Mengubah |
|---|---|---|
| 2026 (TTM) | -63.64 | 136.39% |
| 2024 | -26.92 | -2.51% |
| 2023 | -27.61 | 9.90% |
| 2022 | -25.12 | 251.26% |
| 2021 | -7.15 | 102.54% |
| 2020 | -3.53 | 159.10% |
| 2019 | -1.36 | -65.37% |
| 2018 | -3.94 | 8.81% |
| 2017 | -3.62 | -51.09% |
| 2016 | -7.40 | 251.41% |
| 2015 | -2.10 | -51.84% |
| 2014 | -4.37 | 161.58% |
| 2013 | -1.67 | 6.81% |
| 2012 | -1.56 | -37.32% |
| 2011 | -2.50 | 9.80% |
| 2010 | -2.27 | -8.40% |
| 2009 | -2.48 | -29.73% |
| 2008 | -3.53 | 63.36% |
| 2007 | -2.16 | -51.35% |
| 2006 | -4.44 | -103.30% |
| 2005 | 134.44 | 0.00% |
Rasio P/E untuk perusahaan serupa atau pesaing
| Perusahaan | Rasio P/E | Perbedaan Rasio P/E | Negara |
|---|---|---|---|
| 28.78 | -145.23% |
US
|
|
| -28.36 | -55.44% |
US
|
|
| -24.57 | -61.40% |
AU
|
|
| - | - |
CH
|
|
| 30.33 | -147.66% |
NL
|
Bagaimana cara membaca P/E ratio?
Rasio Harga/Laba (P/E) mengukur hubungan antara harga saham perusahaan dan laba per sahamnya.
P/E yang rendah namun positif menunjukkan perusahaan dengan laba tinggi dibandingkan valuasinya saat ini dan mungkin dianggap undervalued. P/E negatif tinggi (mendekati 0) menunjukkan perusahaan yang mengalami kerugian besar.
Perusahaan dengan P/E di atas 30 atau negatif umumnya dianggap sebagai "saham pertumbuhan", artinya investor mengharapkan pertumbuhan atau keuntungan di masa depan.
Perusahaan dengan P/E positif di bawah 10 dianggap sebagai "saham bernilai", artinya perusahaan sudah sangat menguntungkan dan pertumbuhannya kemungkinan tidak besar.